Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 4/20 | 0.64 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | PLG | P00747 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.46 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.46 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7004889 | 1.00 | PAOX (0.64) | PAOXMAOAMAOBALDH1A1ALOX15 | |
| SCHEMBL7010157 | 1.00 | PAOX (0.64) | PAOXMAOAMAOBALDH1A1ALOX15 | |
| SCHEMBL7007901 | 1.00 | PAOX (0.64) | PAOXMAOAMAOBALDH1A1ALOX15 | |
| SCHEMBL16247098 | 1.00 | PAOX (0.64) | PAOXMAOAMAOBALDH1A1ALOX15 | |
| SCHEMBL944344 | 1.00 | PAOX (0.64) | PAOXMAOAMAOBALDH1A1ALOX15 | |
| SCHEMBL1389554 | 1.00 | PAOX (0.64) | PAOXMAOAMAOBALDH1A1ALOX15 | |
| SCHEMBL3065839 | 1.00 | PAOX (0.64) | PAOXMAOAMAOBALDH1A1ALOX15 | |
| Hydrochloric Acid SCHEMBL25353689 | 0.98 | PAOX (0.61) | PAOXMAOAMAOBALDH1A1ALOX15 | |
| Hydrochloric Acid SCHEMBL15155878 | 0.98 | PAOX (0.61) | PAOXMAOAMAOBALDH1A1ALOX15 | |
| Ammonia Solution, Strong SCHEMBL8683457 | 0.98 | PAOX (0.61) | PAOXMAOAMAOBALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673438-A1 | PROTEOLYSIS-TARGETING CHIMERAS | Tocris Cookson Limited (GB) | 2026-01-07 | — | — | EP | disclosed |
| WO-2024180157-A1 | PROTEOLYSIS-TARGETING CHIMERAS | TOCRIS COOKSON LIMITED (GB) | 2024-09-06 | — | — | WO | disclosed |
| US-20240190790-A1 | CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING | REILEY PHARMACEUTICALS INC (US) | 2024-06-13 | — | — | US | disclosed |
| EP-3584576-B1 | BIS-BIOTIN AND BIS-IMINOBIOTIN DERIVATIVES AS LABELS FOR IDENTIFICATION OF POTENTIAL DRUG TARGET PROTEINS FOR DEVELOPMENT OF ANTIBODY DRUGS | MITSUI CHEMICALS INC (JP) | 2024-05-22 | — | — | EP | disclosed |
| EP-4334307-A1 | CDK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-11905291-B2 | — | — | 2024-02-20 | — | — | US | disclosed |
| WO-2024010776-A1 | AGENTS WITH TRANSCRIPTION FACTOR TARGETING MOIETIES | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| US-11833208-B2 | PLK1 selective degradation inducing compound | UPPTHERA, INC. (KR) | 2023-12-05 | — | — | US | disclosed |
| US-20230372498-A1 | PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND | UPPTHERA (KR) | 2023-11-23 | — | — | US | disclosed |
| WO-2023091565-A1 | NSD2-TARGETED CHEMICAL DEGRADERS AND COMPOSITIONS AND METHODS OF USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20180162784-A1 | CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING | Reiley Pharmaceuticals, Inc. | 2018-06-14 | — | — | US | disclosed |
| WO-2018006074-A2 | COMPOUNDS AND METHODS FOR MODULATING RNA FUNCTION | ARRAKIS THERAPEUTICS, INC. (US) | 2018-01-04 | — | — | WO | disclosed |
| US-9850183-B2 | Conjugates derived from non-steroidal anti-inflammatory drugs and methods of use thereof in imaging | Reiley Pharmaceuticals, Inc. (US) | 2017-12-26 | — | — | US | disclosed |
| WO-2017136450-A2 | COMPOUNDS AND METHODS OF TREATING RNA-MEDIATED DISEASES | ARRAKIS THERAPEUTICS, INC. (US) | 2017-08-10 | — | — | WO | disclosed |
| WO-2017053982-A1 | TRIPTYCENE DERIVATIVES FOR NUCLEIC ACID JUNCTION STABILIZATION | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-03-30 | — | — | WO | disclosed |
| US-20150374858-A1 | CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING | Reiley Pharmaceuticals, Inc. | 2015-12-31 | — | — | US | disclosed |
| US-20030225007-A1 | Sulfonamide derivatives of 3-substituted imidazol[1,2-d]-1,2,4-thiadiazoles and 3-substituted-[1,2,4] thiadiazolo[4,5-a] benzimidazole as inhibitors of fibrin cross-linking and transglutaminases | APOTEX INC. | 2003-12-04 | — | — | US | disclosed |
| EP-1348710-A1 | Sulfonamide derivatives of 3-substituted imidazo[1,2-D]-1,2,4-thiadiazoles and 3-substituted-[1,2,4]thiadiazolo[4,5-A]benzimidazole as inhibitors of fibrin cross-linking and transglutaminases | Apotex Inc. (CA) | 2003-10-01 | — | — | EP | disclosed |
| US-5350864-A | Aminoalkylcarbamyl derivatives of forskolin as intermediates for the synthesis of useful forskolin derivatives | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-09-27 | — | — | US | disclosed |
| WO-1991017154-A1 | AMINOALKYLCARBAMYL DERIVATIVES OF FORSKOLIN AS INTERMEDIATES FOR THE SYNTHESIS OF USEFUL FORSKOLIN DERIVATIVES | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, UNITED STATES DEPARTMENT OF COMMERCE (US) | 1991-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372498-A1 | PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | PAOX 1292/4885MAOA 2981/4885MAOB 3258/4885 |
| US-20180162784-A1 | CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING | PTGES3, PTGES, HPGDS | PAOX 1362/4885MAOA 1831/4885MAOB 2221/4885 |
| US-11905291-B2 | — | WDR5, WDR48, WDR1 | PAOX 2615/4885MAOA 4647/4885MAOB 4631/4885 |
| US-20150374858-A1 | CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING | PTGES3, PTGES, HPGDS | PAOX 1362/4885MAOA 1831/4885MAOB 2221/4885 |
| US-20240190790-A1 | CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING | PTGES3, PTGES, HPGDS | PAOX 1362/4885MAOA 1831/4885MAOB 2221/4885 |
| US-20030225007-A1 | Sulfonamide derivatives of 3-substituted imidazol[1,2-d]-1,2,4-thiadiazoles and 3-substituted-[1,2,4] thiadiazolo[4,5-a] benzimidazole as inhibitors of fibrin cross-linking and transglutaminases | PIGS, FGB, SERPINE1 | PAOX 2902/4885MAOA 1597/4885MAOB 2556/4885 |
| US-11833208-B2 | PLK1 selective degradation inducing compound | PLK1, BUB1B, BUB1 | PAOX 1292/4885MAOA 2981/4885MAOB 3258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.